Abstract:Natural, extracellular membrane vesicles secreted by Gram-negative bacteria, outer membrane vesicles (OMVs), contain numerous pathogen-associated molecular patterns which can activate systemic immune responses. Previous studies have shown that OMVs induce strong IFN-γ- and T cell-mediated anti-tumor effects in mice. However, IFN-γ is known to upregulate immunosuppressive factors in the tumor microenvironment, especially the immune checkpoint programmed death 1 ligand 1 (PD-L1), which may hamper T cell function and limit immunotherapeutic effectiveness. Here, we report the development of genetically engineered OMVs whose surface has been modified by insertion of the ectodomain of programmed death 1 (PD1). This genetic modification does not affect the ability of OMVs to trigger immune activation. More importantly, the engineered OMV-PD1 can bind to PD-L1 on the tumor cell surface and facilitate its internalization and reduction, thereby protecting T cells from the PD1/PD-L1 immune inhibitory axis. Through the combined effects of immune activation and checkpoint suppression, the engineered OMVs drive the accumulation of effector T cells in the tumor, which, in turn, leads to a greater impairment of tumor growth, compared with not only native OMVs but also the commonly used PD-L1 antibody. In conclusion, this work demonstrates the potential of bioengineered OMVs as effective immunotherapeutic agents that can comprehensively regulate the tumor immune microenvironment to effect markedly increased anti-tumor efficacy.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acsnano.0c03776?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acsnano.0c03776</a>.Additional figures for further characterization of OMVs and OMV-PD1 (Supplementary Figure 1); BMDCs mature, TLRs response, and CD49b+ NK cells quantification (Supplementary Figures 2, 3, and 4); PD-L1 upregulation in tumor cells in response to OMVs or IFN-γ (Supplementary Figure 5); immunoprecipitation results with OMVs and OMV-PD1 (Supplementary Figure 6); cell-binding and uptake studies (Supplementary Figures 7 and 8); intracellular fate of OMVs and OMV-PD1 (Supplementary Figure 9); proportion of proliferative T cells (Supplementary Figure 10); OMV-PD1 blood retention time (Supplementary Figure 11); cytotoxicity on B16, CT26, and HUVEC (Supplementary Figure 12); B16 and CT26 tumor images and average body weight (Supplementary Figure 13); analysis of effector memory T cells (CD3+CD8+CD44+CD62L–), CD49b+ cells, and CD11b+ cells (Supplementarys Figure 14 and 15); quantification analysis of PDL1 (Supplementary Figure 16); percentage of IFN-γ+CD8+ T cells (Supplementary Figure 17); biosafety of OMVs (Supplementary Figures 18 and 19); effects of immunotherapy on organ histology (Supplementary Figure 20); and Pearson's colocalization coefficiencts (PCC) of PD-L1 and acid compartments (Supplementary Table 1) (<a class="ext-link" href="/doi/suppl/10.1021/acsnano.0c03776/suppl_file/nn0c03776_si_001.pdf">PDF</a>)This article has not yet been cited by other publications.

Protective cellular immunity generated by cross-presenting recombinant overlapping peptide proteins

Targeted Delivery of Nanovaccine to Dendritic Cells Via DC-Binding Peptides Induces Potent Antiviral Immunity in Vivo

In Vitro and In Vivo Antigen Presentation and Diagnosis Development of Recombinant Overlapping Peptides Corresponding to Mtb ESAT-6/CFP-10

Engineered protein destabilization reverses intrinsic immune evasion for candidate vaccine pan-strain KSHV and SARS-CoV-2 antigens

Targeting Cross-Presentation as a Route to Improve the Efficiency of Peptide-Based Cancer Vaccines

Immune Adjuvant Targeting Micelles Allow Efficient Dendritic Cell Migration to Lymph Nodes for Enhanced Cellular Immunity.

Bioengineered Bovine Papillomavirus L1 Protein Virus-like Particle (VLP) Vaccines for Enhanced Induction of CD8 T Cell Responses through Cross-Priming

Priming with Raav Encoding Rbd of Sars-Cov S Protein and Boosting with Rbd-Specific Peptides for T Cell Epitopes Elevated Humoral and Cellular Immune Responses Against Sars-Cov Infection

DC-Based Vaccines for Cancer Immunotherapy

Polyethyleneimine modification of aluminum hydroxide nanoparticle enhances antigen transportation and cross-presentation of dendritic cells.

Bacterial Outer Membrane Vesicles Presenting Programmed Death 1 for Improved Cancer Immunotherapy via Immune Activation and Checkpoint Inhibition

CD4 + T-cell epitope-based heterologous prime-boost vaccination potentiates anti-tumor immunity and PD-1/PD-L1 immunotherapy

Direct Priming of CD8+ T Cells Persists in the Face of Cowpox Virus Inhibitors of Antigen Presentation

Heterologous Prime-Boost with Immunologically Orthogonal Protein Nanoparticles for Peptide Immunofocusing

Dendronized polymer conjugates with amplified immunogenic cell death for oncolytic immunotherapy

Boosting PRRSV-Specific Cellular Immunity: The Immunological Profiling of an Fc-Fused Multi-CTL Epitope Vaccine in Mice

Cell Penetrating Peptide-Based Redox-Sensitive Vaccine Delivery System for Subcutaneous Vaccination

Coordinating Antigen Cytosolic Delivery and Danger Signaling to Program Potent Cross-Priming by Micelle-Based Nanovaccine

Optimized mobilization of MHC class I- and II- restricted immunity by dendritic cell vaccine potentiates cancer therapy

A scaffold vaccine to promote tumor antigen cross-presentation via sustained toll-like receptor-2 (TLR2) activation

Vaccination against neoantigens induced in cross-priming cDC1 in vivo